The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

[1]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[2]  F. Morrone,et al.  Gender differences, polypharmacy, and potential pharmacological interactions in the elderly , 2011, Clinics.

[3]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Kerr,et al.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Booton,et al.  The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Bezjak,et al.  The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates , 2010, Cancer.

[9]  K. Armstrong,et al.  Gender Influences Treatment and Survival in Colorectal Cancer Surgery , 2009, Diseases of the colon and rectum.

[10]  H. Lenz,et al.  Gender Disparities in Metastatic Colorectal Cancer Survival , 2009, Clinical Cancer Research.

[11]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Kneebone,et al.  Improved Survival in Young Women With Colorectal Cancer , 2008, The American Journal of Gastroenterology.

[13]  L. Påhlman,et al.  The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. , 2007, Critical reviews in oncology/hematology.

[14]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Colditz,et al.  Hormone replacement therapy and survival after colorectal cancer diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Nancy Breen,et al.  Patterns of Colorectal Cancer Screening Uptake among Men and Women in the United States , 2006, Cancer Epidemiology Biomarkers & Prevention.

[17]  J. Wardle,et al.  Gender differences in utilization of colorectal cancer screening , 2005, Journal of medical screening.

[18]  F. Shepherd,et al.  Influence of sex on toxicity and treatment outcome in small-cell lung cancer. , 2005, Journal of Clinical Oncology.

[19]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[20]  C. McArdle,et al.  Male gender adversely affects survival following surgery for colorectal cancer , 2003, The British journal of surgery.

[21]  S. Cha,et al.  Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Wichmann,et al.  Gender differences in long‐term survival of patients with colorectal cancer , 2001, The British journal of surgery.

[23]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[24]  J. Sloan,et al.  Sex differences in fluorouracil-induced stomatitis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  X. Pivot,et al.  Cisplatin Nephrotoxicity: A Multivariate Analysis of Potential Predisposing Factors , 1997, Pharmacotherapy.

[26]  S. Barni,et al.  Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients , 1997, Supportive Care in Cancer.

[27]  F. Demard,et al.  Influence of sex and age on fluorouracil clearance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.